Abstract This review concerns methods of synthesis, NMR analysis and applications of isotope-labelled hydantoins. The hydantoin moiety is present in natural products and in extraterrestrial ice, indicating this to be an important compound in prebiotic chemistry. Bacterial transport proteins that scavenge hydantoins have been identified, isolated and characterised with isotope-labelling of hydantoins as an essential requirement to achieve this. These are Mhp1 from Microbacterium liquefaciens and PucI from Bacillus subtilis, transporting 5-arylsubstituted hydantoins and allantoin, respectively. The hydantoin ring is a useful centre in synthetic chemistry, especially for combinatorial chemistry, multicomponent reactions and in diversity-oriented synthesis. It is also found in pharmacologically active molecules, such as the anticonvulsant phenytoin. Hydantoins synthesised with isotope labels include hydantoin itself, allantoin, other 5-monosubstituted derivatives, phenytoin, other 5,5-disubstituted derivatives, N-substituted derivatives and other more complex molecules with multiple substituents. Analysis of isotope-containing hydantoins by NMR spectroscopy has been important for confirming purity, labelling integrity, specific activity and molecule conformation. Isotope-labelled hydantoins have been used in a range of biological, biomedical, food and environmental applications including metabolic and in vivo tissue distribution studies, biochemical analysis of transport proteins, identification and tissue distribution of drug binding sites, drug metabolism and pharmacokinetic studies and as an imaging agent.
INTRODUCTION
1 ydantoin (IUPAC name imidazolidine-2,4-dione) (1) (Figure 1 ) is a heterocyclic ring system that occurs relatively rarely in nature. The most commonly known natural product with the hydantoin ring is the urea derivative allantoin (5-ureidohydantoin) (2) (Figure 1 fungi, plants and animals. Allantoin is also present in a number of toothpastes, mouth washes, shampoos and cosmetic products and is used in medications that treat skin conditions including acne, impetigo, eczema and psoriasis. Other natural products that contain the hydantoin ring as part of their chemical structure have been isolated from marine sponges [1, 2] , from a Mediterranean Sea anemone [3] and from the fungus Fusarium sp [4] . A fulvic acid polymer isolated from a coastal pond in Antarctica is also suggested to contain a hydantoin ring based on a solid-state NMR 15 N and 13 
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N} chemical shift investigation [5] . Interestingly, the presence of hydantoin in extraterrestrial ice has been demonstrated, indicating this to be an important compound in prebiotic chemistry [6] , and a new route for the prebiotic synthesis of hydantoin in water/ice/urea solutions involving the photochemistry of acetylene has been proposed [7] . The first reported synthesis of hydantoin was in 1861 by Baeyer [8] , but its structure was not assigned correctly until 1870 by Strecker [9] . The chemical properties, methods of synthesis and reactivity of hydantoin and its derivativies have been reviewed extensively [10] [11] [12] [13] [14] [15] . For synthetic chemistry applications, hydantoin is a useful centre in combinatorial chemistry [16] , multicomponent reactions [17, 18] and in diversity-oriented synthesis [19] [20] [21] . Hydantoins substituted at the 5-position are precursors to optically pure natural and unnatural α-amino acids, which is achieved through their chemical or enzymatic hydrolysis [22] [23] [24] [25] [26] [27] [28] [29] [30] . They therefore serve as important compounds in the food industry, for example in the production of the artificial sweetener aspartame (N-(L-α-aspartyl)-L-phenylalanine, 1-methyl ester), which can be synthesised from its constituent L-α-amino acids. They are important in the pharmaceutical industry as precursors to optically pure D-amino acids [31] [32] [33] , which are used in the production of certain drugs such as β-lactam antibiotics (e.g. penicillin and amoxicillin) and anticancer agents (e.g. goserelin). The hydantoin moiety itself also forms the basis or is a constituent of a number of pharmacologically active molecules, the most well known being anticonvulsants such as phenytoin (5,5-diphenylhydantoin) (3) (Figure 1 ) [34] [35] [36] [37] .
Patching
A protein called Mhp1 that promotes the uptake of 5-aryl substituted hydantoins into cells of the Gram positive bacterium Microbacterium liquefaciens, serving as part of a salvage pathway for carbon nutrients, has been identified, isolated and purified and its high-resolution crystal structure ( Figure 2A ) determined in three different conformations (open to outside, occluded with substrate, open to inside), the first for any secondary active transport protein [38] [39] [40] [41] [42] [43] . Mhp1 is a member of the widespread nucleobase-cation-symport-1 (NCS1) family of secondary active transport proteins with members in bacteria, fungi and plants [44] [45] [46] [47] [48] [49] [50] [51] [52] and has provided a pivotal model for the alternating access mechanism of membrane transport and for the mechanism of ion-coupling [41, 42, [53] [54] [55] [56] [57] . Mhp1 is located in the cytoplasmic cell membrane where it catalyses the inward co-transport of a sodium ion down its concentration gradient and of a hydantoin molecule against its concentration gradient ( Figure 2A ). This mechanism enables the bacterium to scavenge low concentrations of hydantoin compounds from its environment. The principal transported substrates of Mhp1 are L-5-benzylhydantoin (4) and L-5-indolylmethylhydantoin (5) ( Figure 2B ). [62] . Mhp1 is shown in a cell membrane where it catalyses the inward co-transport of a sodium ion (purple circle) down its concentration gradient and of a hydantoin molecule (green circle) against its concentration gradient. This mechanism enables the bacterium to scavenge low concentrations of hydantoin compounds from its environment for use as sources of carbon and nitrogen. The locations of a sodium ion and of a hydantoin molecule can be seen in the centre of the structure at their respective binding sites. The structure of Mhp1 was drawn using RSCB Protein Data Bank (http://www.rcsb.org/pdb/home/home.do) file 4D1A using Jmol [63] . B.
Substrates of the Mhp1 transport protein
An allantoin transport protein called PucI from Bacillus subtilis has recently been isolated, purified and characterised [58] . PucI shares evolutionary relationships with other putative bacterial allantoin permeases, with Mhp1 and with other characterised NCS1 transporters in fungi and plants [58] .
Crucial to the success in characterising the ligand recognition, substrate selectivity and transport kinetics of Mhp1 and PucI was synthesis of a number of isotope-labelled hydantoins and their use in biochemical assays [39, [58] [59] [60] [61] [62] . Analysis of the synthesised isotope-containing hydantoin compounds by NMR spectroscopy was important for confirming their purity and labelling integrity. A significant number and variety of Patching other isotope-labelled hydantoins have been synthesised and used in a range of biological, biomedical, food and environmental applications. The methods of synthesis, NMR analysis and their applications are the subject of this review.
HYDANTOIN
A classic method for the synthesis of hydantoin uses glycine as the starting compound ( Figure 3 , Scheme 1). Glycine (6) is reacted with ethanol/acid to give the ester (7); the amine group is then reacted with potassium cyanate to give the intermediate (8) , which is cyclised under acid reflux to give hydantoin (1 1a, 1b, 1c) , respectively [64] [65] [66] .
The [4- 13 C]hydantoin and [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] N]hydantoin were reacted with indole-3-aldehyde followed by hydrolysis to give DL-tryptophan labelled with 13 C at the 1-position [64] or with 15 N at the α-N position [66] , respectively. The [5- 14 C]hydantoin was reacted with furfural (9) to give [5- 14 C]5-(2-furylidene)hydantoin (10) and reduced to [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]5-(2-furyl)hydantoin (11) , which was hydrolysed to DL-[2- 14 C]3-(2′-furyl)-alanine ( Figure 3 , Scheme 1) [65] . Another classic method for the synthesis of hydantoin, and derivatives thereof substituted at the 5-position, is the Bucherer-Bergs reaction [67] [68] [69] . This is the multicomponent reaction of carbonyl compounds (aldehydes or ketones) or cyanohydrins with potassium cyanide and ammonium carbonate to give hydantoins where the chemical groups on the carbonyl compound become the substituents at the 5-position in the hydantoin ( Figure 3 , Scheme 2). Use of the simplest aldehyde formaldehyde in this reaction does give hydantoin (1), but also other products including hydantoic acid and hydantoic amide [70] . Work by Winstead et al [71] nicely demonstrates the range of aliphatic, aromatic and cyclic substituted hydantoins that can be produced by the Bucherer-Bergs reaction, which in this case were labelled with the positron emitting carbon-11 at the 4-position by using [ [73, 74] . A similar approach has been used for synthesis of [1- 14 C]-DL-tyrosine [75, 76] . A tritiated form of 5-indolylmethylhydantoin (5a) has been prepared by combining hydantoin (1) with indole-3-carboxaldehyde (18) and the resultant alkene (19) then reduced with tritium gas to give [5, H]-5-indolylmethylhydantoin (5a) (Figure 4 , Scheme 5). This was then converted into [2, H]-DL-tryptophan [77] . Using a method based on Gaudry's synthesis [78] , another 14 C-labelled amino acid, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]-L-lysine, was prepared via the intermediates 5-hydroxyhydantoin and 5-bromobutylhydantoin [79] . A hydantoin with a 123m-tellurium labelled 5-substituent (23) Te]-DL-α-amino--(phenyltelluro)-butyric acid, which was used as a potential pancreatic imaging agent [80] . (2) has been synthesised with 13 C or 14 C labels using urea as the source of the label ( Figure 5 , Scheme 7) [59] . This synthesis began by reduction of parabanic acid (24) to give 5-hydroxyhydantoin, which was then treated with thionyl chloride to give 5-chlorohydantoin (25) . Reaction with [ , 2b) . In this case, NMR analysis was not only important for demonstrating high purity of the labelled product, but the 13 C NMR spectrum of 2a ( Figure 6A ) also revealed a partial scrambling of the 13 C label from the ureido group (157.7 ppm) to the C-2 position (157.1 ppm) [59] . This confirmed a rearrangement of allantoin in solution via a putative bicyclic intermediate [81] and so 2a was assigned as DL-[H2N 13 CO/ synthesised by the same method was therefore also assigned as DL-[H2N 14 CO/ 14 C-2]allantoin [59] . The 14 C-labelled compound has been used in whole cell uptake assays with the transport proteins Mhp1 and PucI in experiments to define their substrate selectivities, ligand recognition and transport kinetics ( Figure 7 ) [58, 62] . Crucially, these measurements provided the first experimental evidence to demonstrate that PucI is a medium-affinity transporter of allantoin. The Mhp1 substrates L-5-benzylhydantoin (4) and L-5-indolylmethylhydantoin (5) have been synthesised containing both 13 C and 14 C labels ( Figure 5 ) for use in solid-state NMR measurements of ligand binding (unpublished) and in whole cell transport assays, respectively, with the Mhp1 protein [60, 62] . These compounds were prepared from the appropriate L-α-amino acid (phenylalanine or tryptophan) by reaction with potassium cyanate under acidic conditions to give the Lcarbamoyl-L-α-amino acid, which was then cyclised to give the 5-substituted L-hydantoin ( Figure 5 , Scheme 8). This is based on the classic Urech hydantoin synthesis [82] . [6-
DL-Allantoin
C]-Ltryptophan. NMR analysis of the 13 C-labelled compounds was important for confirming both high purity and labelling integrity [60] . The 13 C NMR spectrum of [6- 13 C]-L-5-benzylhydantoin (4a) confirmed 13 C enrichment exclusively in the C-6 position at 36.8 ppm and the 1 H NMR spectrum showed a splitting of the H-6 methylene signal at 2.94 ppm with a coupling constant of 129 Hz due to the directly attached 13 C label ( Figure 6B ). Similarly, the 13 C NMR spectrum of [indole-2- 13 C]-L-5-indolylmethylhydantoin (5b) confirmed 13 C enrichment exclusively in the indole-C2 position at 124.5 ppm and the 1 H NMR spectrum showed a splitting of the indole-H2 signal at 7.14 ppm with a coupling constant of 181 Hz due to the directly attached 13 C label ( Figure 6C ). The 14 C-labelled versions of the compounds (4b, 5c) were prepared by using [ 14 C]potassium cyanate in the reaction to introduce the label at C-2 in the hydantoin ring [60] . These 14 C-compounds have been used in whole cell uptake assays with Mhp1 that have been crucial in defining its substrate selectivity, ligand recognition and quantitation of ligand binding and in screening the transport activities of Mhp1 mutants ( Figure  7 ). This work also identified a novel inhibitor of Mhp1, 5-(2-naphthylmethyl)hydantoin, which was itself synthesised with a 14 C label at the C-2 position using the same method ( Figure 7 ) [62] .
A hydantoin derivative of DL-canaline has been synthesised with a [83] . The synthesis began by reacting acrolein (27) and ethyl N-hydroxyacetimidate (28) to give ethyl N- [3-oxopropoxy] acetimidate (29) , which is converted into the nitrile (30) using [
Patching
The nitrile was cyclised with ammonium carbonate to give the 14 C-labelled hydantoin (31) . Heating of the hydantoin with sodium hydroxide afforded [1-
which was intended for use in evaluating its capacity to support amino acid biosynthesis by a seed-eating beetle. 13 C Chemical shift (ppm) 13 
PHENYTOIN AND DERIVATIVES
The hydantoin that has been isotope-labelled and used in biomedical applications with highest proliferation is the anticonvulsant drug phenytoin (5,5-diphenylhydantoin) (3). A wide range of different isotope labels, labelling patterns and synthetic routes have been used with phenytoin and with derivatives of phenytoin.
Phenytoin with all three carbon positions in the hydantoin ring 13 C-labeled has been synthesised with [ 
Substrate selectivity Mutant screening Transport kinetics
Patching labelled biomedical tracer using mass spectrometry for detection; this was prior to the availability of a radiolabelled form of phenytoin. Later, both Emran et al [85] and Iida et al [86] used the same reaction of benzoin (37b) with 11 C-or 13 C-labelled urea (26a, 26b) to produce [2- C label at the 4-position and these were used in measurements of their in vivo distribution [89] . The brain and whole-body pharmacokinetics of the 11 C-labelled 5,5-diphenylhydantoin in rats has been evaluated using a planar positron imaging system (Figure 9 ), which demonstrated a difference in the brain distribution of the compound between intravenous and duodenal administration [90] . [91] . Using a similar approach but starting with d6-benzene (43b), a deuterated form of phenytoin has been synthesised with all aromatic hydrogen atoms replaced by deuterium (3f) (Figure 8 , Scheme 14) [92] . The same compound has also been produced more directly by reacting parabanic acid (24) with d6-benzene (43b) and triflic acid (Figure 8 , Scheme 14) [93] . This work also prepared a number of deuterated derivatives of phenytoin, for example 3g. Phenytoin with deuteration of just one phenyl ring has been synthesised by Grignard production from d6-benzene (43b) and coupling with benzoylformaldehyde (46) to give d5-benzoin (37c) which was converted into d5-benzil (47) and then condensed with urea (26c) to give 5-(d5-phenyl)-5-phenylhydantoin (3h) (Figure 10 , Scheme 15) [94] . This compound was used as a probe in metabolic studies and as an internal standard for combined GC-MS-computer analyses of body fluid extracts. The synthesis of the 3-hydroxyphenyl and 4-hydroxyphenyl metabolites of phenytoin labelled with deuterium in either of the two phenyl rings (48a, 48b, 49a, 49b ) and of 5-(d5-phenyl)-5-(d4-p-hydroxyphenyl)-hydantoin (48c) (Figure 10 ) has been achieved by coupling the appropriate labelled and unlabelled components in the production of benzophenone followed by its use in a Bucherer-Bergs reaction (Figure 10 , Scheme 16) [95] . The synthesis of phenytoin with a deuterium or tritium atom exclusively at the para position of both phenyl rings has been achieved by Bucherer-Bergs reaction with p-bromobenzophenone (50) to give 5,5-di-(4-bromophenyl)hydantoin (51) which was then reduced in the presence of deuterium oxide or tritium gas, replacing the bromines to give 5,5-di-(4-2 H-phenyl)hydantoin (3i) [96] or 5,5-di-(4-3 H-phenyl)-hydantoin (3j) [97] , respectively ( Figure 10, Scheme 17 ). In the case of the deuterated form, for materials with isotopic content up to 95%, excellent agreement was found between the data obtained by mass spectrometry and 13 C-nuclear magnetic resonance operated in a NOE-suppression mode. Phenytoin has also been tritiated directly using 3 H2O and platinum catalyst (from the dioxide and sodium borohydride) and the pattern of labelling was defined by 3 H NMR spectroscopy [98] . An elegant seven-step synthesis has been used to prepare the separate enantiomers of phenytoin with a single deuterium atom at the ortho-position in only one of the phenyl groups ( Figure 11 , Scheme 18) [99] . The bromine atom of 3-bromoanisole (52) was substituted for deuterium by reduction with deuterium gas and the resultant [3- (Schemes 15-17) . A synthesis of phenytoin with a deuterium atom at the ortho-position on both phenyl groups has also been achieved ( Figure 12 , Scheme 19) [101] . 2-Bromotoluene (58) was converted to the Grignard reagent and then decomposed with deuterium oxide to give [2-2 H]toluene (59a) which was converted in three steps to H]benzaldehyde (36b). This was converted into the dideuterobenzoin (37d) and then dideuterobenzil which was rearranged to the dideuterobenzilic acid (60) before condensing with urea (26b) to give 5,5-di-[2-2 H]phenylhydantoin (3m). A deuterium atom at the orthoposition in phenytoin is more stable to metabolism than at other positions and therefore more suitable to use in metabolic studies that are followed by mass spectrometry. A number of isotope-labelled derivatives of phenytoin with more complex substituents have also been synthesised. These include a series of 125 I-labelled N3-substituted acetamido-tyrosine ethyl ester derivatives (61) used as iodinated tracers in a radioimmunoassay for phenytoin [102, 103] 
OTHER 5,5-DISUBSTITUTED HYDANTOINS
A number of other 5,5-disubstituted hydantoins have been synthesised and used in a range of different applications. A 13 C-labelled benzylated hydantoin intermediate (66) has been used in the synthesis of the α-adrenergic agonist α-methyldopa with a 13 C label at the benzylic position (67) (Figure 13 , Scheme 20) [105] . A lithio derivative of 3,4-dibenzyloxybenzene (64) was subject to carbonation with [ 13 C]carbon dioxide and the resultant benzoic acid (65) was reduced with lithium aluminium hydride. Oxidation with chromium trioxide gave the benzaldehyde which was condensed with nitroethane to form the phenylnitropropene. Reduction of the phenylnitropropene gave the corresponding phenyl-2-propanone which was converted to the hydantoin (66) . The hydantoin was subject to base hydrolysis followed by debenzylation to give [ 
Scheme 19
Patching chloride derivative (69) with deuterium or tritium gas. The pharmacologically active S-(+)-enantiomer was isolated by brucine resolution [100] . 5-Ethyl-5-phenylhydantoin has been synthesised with deuterium labelling at the methyl group (71a) or in the phenyl group (71b) or with a 14 C-label at the C-4 position (71c) (Figure 13 ) during synthesis of the antimuscarinic drug trimebutine and its metabolites with deuterium and 14 C labels [107] . The symmetric 5,5-cyclic disubstituted spirodihydantoin has been synthesised with 13 C and 15 N labels in one half of the molecule (74a) [108] using a method by Poje et al [109] (Figure 13, Scheme 22) . Reaction of 4,5,6(1H)-pyrimidinetrione (72) (79) , which was converted to the sulphonyl chloride (80) . This was coupled with a range of amines to give the hydantoin sulphonamide compounds (81) with 13 C labels at C-4, C-5, CH3 and CH2 and 15 N at N-3. The introduction of multiple labels provided a molecule with a greater mass differential from the parent compound that was more useful than a molecule with a single label in the development of bioanalytical methods.
N-SUBSTITUTED HYDANTOINS
Some hydantoins with substituents at the N-1 and/or N-3 position have been synthesised with isotope labels. The hydantoin drug dantrolene (82) , which interferes with release of calcium ions from intracellular stores of skeletal muscle, and a photoaffinity azido analogue (83) have been synthesised with a tritium label at a non-exchangeable imine in the N-1 substituent group (Figure 14) H labelling since the spectra showed no sign of hydrogen at the imine position ( Figure 15A ). It is also reported that the compounds showed no sign of hydrogen/tritium exchange during a period of over one year [111] . The tritiated compounds were used in the identification of a putative skeletal muscle dantrolene binding site in sarcoplasmic reticulum membranes ( Figure 15B ) [111] . Dantrolene is also a substrate for breast cancer resistant protein (BCRP), which is widely distributed in the blood-brain-barrier, intestine, gall bladder and liver. (Figure 14) , respectively, for PET imaging of the receptor glycine binding site [114] . These compounds containing a 1,3-di-N-substituted hydantoin moiety were obtained by alkylation of a phenolic hydroxyl group using [ A 2-nitrobenzaldehyde derivative of 1-aminohydantoin (91) has been synthesised with 13 C labels in the aromatic ring starting from [1, 2, 3, 4, 5, [6] [7] [8] [9] [10] [11] [12] [13] C6]toluene (59b) (Figure 14 , Scheme 24) [115] . The [ 13 C6]toluene (59b) was nitrated using nitronium tetrafluoroborate giving a mixture of ortho and para products (86, 87) which were then simultaneously oxidised using chromium trioxide to give a mixture of [1,2,3,4,5,6- C]HMBC 2D-correlation spectra and a homonuclear NOE difference spectrum exhibited a spatial correlation between the iminyl hydrogen and the hydrogen atoms N-CH2 indicative of an E configuration [115] . This compound was used along with other 13 C-labelled 2-nitrobenzaldehyde derivatives of nitrofuran metabolites as internal standards for the quantification of trace levels of nitrofuran residues by liquid chromatography-tandem mass spectrometry in foods of animal origin [115] . 3-Methyl-2-thiohydantoin (93) has been synthesised with a 14 C label at C-4 in two steps from [1- 14 C]glycine (6d) (Figure 14 , Scheme 25) [116] . Reaction of the glycine with methyl isothiocyanate under basic conditions produced 14 C-labelled 5-methylthiohydantoic acid (92) , which cyclises at acidic pH to [4- 
7.
18 O-LABELLED HYDANTOINS The stable isotope oxygen-18 has been incorporated into some hydantoin compounds. Guanidinohydantoin has been synthesised with 13 C, This isotope labelling of guanidinohydantoin combined with mass spectrometry and NMR analysis helped to resolve controversial issues concerning its structure and suggested potential mechanisms to explain products observed from the oxidation of guanosine by singlet oxygen, which has importance in cancer etiology and its cure by photodynamic therapy. The same work that produced 13 C, 15 N-labelled spirodihydantoin (74a) described above also produced spirodihydantoin (74b), spiroiminohydantoin (97) , allantoin (2b) and guanidinohydantoin (96) with an 18 O label (Figure 16 ) [108] . These compounds were used in an investigation of uric acid metabolism. 
OTHER MORE COMPLEX MOLECULES THAT CONTAIN THE HYDANTOIN MOIETY
A range of compounds containing the hydantoin moiety with multiple and/or complex substituents have been synthesised containing isotope labels.
The separate enantiomers of the anticonvulsant drug 3-methyl-5-ethyl-5-phenylhydantoin (mephenytoin) (98) were synthesised with a 
Scheme 27
Patching nervous system and the deuterated form was required as an internal standard for selected ion monitoring by GC-MS. A DP prostanoid receptor antagonist BWA868C or 3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethyl-amino)hydantoin (102) has been synthesised with tritium labelling in the cyclohexyl group ( Figure 17 ) and then used for characterisation and autoradiographic localisation of DP receptors in a range of mammalian tissues and cells and to better define the distribution and possible functions of DP receptors in the mammalian body [121] . This includes localisation of DP receptors in the human eye ( Figure 18 ) [121] . A -(β-D-erythro-pentofuranosyl)-5-guanidinohydantoin in peroxynitrite oxidized DNA by isotope-dilution mass spectrometry [122] . Compound 103 undergoes pH-and temperature-dependent isomerisation to Patching the iminoallantoin (104) (Figure 17 ), which made its purification especially challenging. A multi-substituted hydantoin nonsteroidal androgen receptor ligand (105) was synthesised with an 11 C label by introduction of the N-1 methyl group in the final step using [ [124] . The key part of the synthesis was a three-step one-pot reaction in which the hydantoin moiety was introduced, the imine oxidized and further hydrolysed to obtain the penultimate precursor to [ Figure 19 ) [125] . Isotope labels were introduced using tritium gas, [ isotope-labelled versions were synthesised for preclinical ADME studies.
The drug lead candidate leukocyte function-associated antigen 1 antagonist spyrocyclic hydantoin: 5-(((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro [4.4] nonan-7-yl)methyl)-thiophene-3-carboxylic acid (110) (Figure 19 ) was synthesised with a 14 C label at the cyano group by substitution of a bromide with [ 14 C]zinc cyanide, prepared from zinc chloride and [ 14 C]potassium cyanide, followed by two further radiochemical steps [126] . Three hydantoin based potent antagonists of lymphocyte function-associated antigen-1 labelled with 14 C and deuterium were synthesised for drug metabolism and pharmacokinetics studies ( Figure  19 ) [127] . (R)-1-acetyl-5-(4-bromobenzyl)-3-(3,5-dichlorophenyl)-5-methyl hydantoin (111) was prepared with a 14 C label at C-2 in the hydantoin ring in two radiochemical steps using [ H, 13 C, 14 C and 15 N labels (108) used as a precursor to conformationally constrained analogues of glutamic acid and 2-oxa and 2-thia-analogues (109), a 14 C-labelled spyrocyclic hydantoin (110) , and antagonists of lymphocyte function-associated antigen-1 with 14 C and/or deuterium labels (111, 114, 116 ).
Patching
A deuterated version of 114 was prepared by reaction of the sulphonyl chloride derivative with d8-piperazine (113) and a deuterated version of 116 was prepared by reaction of the sulphonyl chloride derivative with d9-isonipecotamide (115) . A 125 I-labelled thiohydantoin derivative (117) (Figure 20 ) has been synthesised using [ 125 I]sodium iodide as the source of the label in the last step via an iododestannylation reaction with hydrogen peroxide as the oxidant and used for detecting tau pathology in Alzheimer's disease [128] . In vitro experiments using tau and β-amyloid aggregates showed high specific binding of 117 to tau aggregates and in hippocampal sections of brains from Alzheimer's disease patients, 117 produced intense staining of neurofibrillary tangles (Figure 20) . Furthermore, in experiments using normal mice, 117 showed good uptake into and rapid washout from the brain, suggesting that a 123 I-labelled version of 117 should be investigated as a PET radiotracer for imaging tau pathology [128] . 
CONCLUSIONS
This review of the methods of synthesis, NMR analysis and applications of isotope-labelled hydantoins has confirmed the hydantoin ring system as an important centre in synthetic chemistry and as a component in a variety of different compounds including some with pharmacological activity. In some cases, NMR analysis of the labelled compounds was especially important for confirming purity, labelling integrity and molecule conformation. Hydantoin compounds containing isotope labels have been used in a range of biological, biomedical, food and environmental applications including metabolic and in vivo tissue distribution studies, biochemical analysis of transport proteins, identification and tissue distribution of drug binding sites, drug metabolism and pharmacokinetic studies and as an imaging agent.
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